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Abstract  
 
Background: Laryngeal squamous cell carcinoma (LSCC) is rare in the young.  
Objectives: We characterized the clinical behavior of LSCC and assessed the 
presentation of second primary tumors (SPCs) in this patient population.  
Materials and methods: Data from the Finnish Cancer Registry (FCR) were used to 
identify an epidemiological series of LSCC patients diagnosed at the age of 40 years 
or under, during 1953-2012 in Finland. Data regarding primary treatment, survival 
and SPCs were available. To further characterize the comorbidity and lifestyle factors 
of young patients with LSCC, institutional data was collected of patients treated at the 
Helsinki University Hospital during 1967-2012.  
Results: We identified 151 patients, with a mean follow-up of 252 months. The 10-
year overall survival (OS) was 75% and the disease-specific survival was 84%. SPCs 
were diagnosed in 26% (n=39), with a median delay of 28 years. Of the 35 patients in 
the institutional series from Helsinki, 22 (63 %) were current or former smokers. 
LSCC recurred in 28% of patients.  
Conclusions and Significance: The delay to SPCs in young patients was significantly 
longer compared with the general LSCC population. As factors underlying this 
phenomenon cannot be identified by this retrospective study, further  
studies are warranted.  
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Introduction 
 
Laryngeal squamous cell carcinoma (LSCC) forms one of the largest subgroups of 
head and neck cancer. It typically presents in men (approximately 90% of patients) in 
their sixties (1-4). The cumulative carcinogenic burden of smoking and alcohol 
consumption have been identified as the main risk factors for LSCC: approximately 
90% of patients with LSCC are smokers and the risk of LSCC is 20-fold in smokers 
compared with non-smokers. If smoking presents with alcohol consumption, the risk 
of LSCC is 177-fold (5).  
 
LSCC is rare among young people under the age of 40 years, their occurring in less 
than 10 % of all LSCC patients (2, 4, 6-8).  Prognostic comparisons between young 
LSCC patients and the general LSCC population are inconsistent, perhaps due to 
small sample sizes, different outcome measures and age cut-offs (6, 7, 9, 10). In 
general, LSCC recurs in up to 30% of patients (11, 12). In addition to recurrence, the 
risk for second primary cancers (SPCs) in LSCC patients is high, with an incidence 
exceeding 20% during the first 10 post-treatment years (3). The incidence of SPCs in 
the young LSCC patient population has been reported to be lower compared with the 
general LSCC population, although the reported follow-up times are relatively short 
(2, 7).  
 
Conventional risk factors such as tobacco smoking have been observed as being less 
common in young patients with head and neck squamous cell carcinoma, including 
LSCC (4, 7, 9, 13). This has led to the speculation of other potential etiological 
factors dominating in this patient group such as immunodeficiency, poor oral hygiene 
(10), genomic instability (4, 14), reflux, Helicobacter pylori infection (15), and 
  
occupational carcinogens (4). Studies investigating HPV as a potential risk factor 
have also emerged reporting an HPV incidence of 7.4 to 75% in LSCC samples (16, 
17). However, no causative role for HPV has been identified in LSCC (16, 17). 
 
The present study is a survey of the nationwide Finnish Cancer Registry (FCR) data 
for all patients diagnosed with LSCC at the age of 40 years or under in Finland during 
1953-2012 (n=151) representing one of the largest series on this topic (2, 6-10, 13). In 
addition, an institutional series of patients treated at the Helsinki University Hospital 
(HUH) (n=35) during the years 1967-2014 is reviewed, to shed light on comorbidities 
and lifestyle factors, which were not available in the entire FCR. Our primary aim 
was to investigate the incidence, possible etiological factors, survival and subsequent 
cancer events (recurrences and SPCs) in young patients with LSCC.  
 
  
  
Materials and Methods  
Patient selection flow for the study is presented in Figure 1.  
 
Patient data – the Finnish Cancer Registry 
For nationwide epidemiological analysis, data on all patients diagnosed with LSCC at 
the age of 40 years or under in Finland during 1953 to 2012 were collected from the 
Finnish Cancer Registry (FCR) and reviewed. Data on follow-up time, cause of death 
and possible SPCs were available for all patients. Stage and grade of the tumors, as 
well as the given treatment, were more heterogeneously reported, and thus 
unavailable for comparative analyses.  
 
Patient data – institutional series, Helsinki University Hospital (HUH)  
Clinical data on all patients who had been diagnosed with LSCC at the age of 40 or 
under, during the period between the 1st January 1967 and 31st December 2013 at the 
HUH, Helsinki, Finland, were retrospectively reviewed. Data on this institutional 
patient population were retrieved to supplement the lacking information in the FCR 
data regarding etiological factors and LSCC recurrence. A total of 35 patients at the 
age of 40 years or under were diagnosed and treated for LSCC at HUH.  
The hospital records were reviewed for patient demographics including possible 
etiological factors, such as smoking, drinking and comorbidities as well as LSCC 
recurrence. 
 
Statistical analyses 
Statistical analyses were conducted with the SPSS statistical package (version 20, 
IBM corporation, USA). Survival outcomes were calculated with the Kaplan-Meier 
  
method from the diagnosis to the first event. For overall survival (OS), death 
regardless of cause was used as an event. For disease-specific survival (DSS), death 
from LSCC was used as an event.  
 
Ethical considerations 
An institutional research permission was granted for the study protocol. Due to the 
study design (retrospective chart review) formal Research Ethics Board approval was 
not warranted, in accordance with the Finnish legislation.  
 
 
 
  
  
Results 
Finnish Cancer Registry data 
There were 151 patients identified from the FCR. Patient and tumor characteristics are 
shown in Table 1. The incidence of LSCC in this age group was 0.1/100 000/year in 
men and 0.01/100 000/year in women. The mean follow-up time was 21 years 
(median 21; range, 0.3-59). The treatment of patients according to tumor stage is 
summarized in Table 2. The 5- and 10-year overall survival (OS) was 84% and 75%, 
respectively (Figure 2). The 5- and 10-year disease-specific survival (DSS) was 88% 
and 84 %, respectively (Figure 3). The 5- and 10-year OS and DSS, stratified by 
tumor localization and stage, are presented in Table 3. The treatment outcome for 
Stage 0-II patients and supraglottic primary location patients was excellent, with 5- 
and 10-year DSS figures over 90%. For Stage III-IV and supraglottic LSCC patients 
the figures were significantly lower.  
Thirty-nine (26%) of the patients developed SPCs. The mean time from the diagnosis 
of LSCC to the diagnosis of the SPC was 28 years (median, 28; range, 6-45). The 
localizations of SPCs are shown in Table 3 and their incidence according to follow-up 
time in Figure 4. The most common sites for SPCs were the lungs and trachea (14 
patients; 36% of all SPCs). Five patients presented with further primary tumor(s) after 
the SPC (3% of all patients, 13 % of patients with SPCs). 
 
Helsinki University Hospital (HUH) institutional data 
Thirty-five young LSCC patients were treated at the HUH during 1967-2014, of 
whom seven (20%) were female and 28 (80%) male. The age range of the patients 
was 18-40 years. Of the 35 patients with adequate information on smoking, only six 
(17%) had never smoked. For 15 (43%) patients’ information on the duration of 
  
smoking was available with a mean of 19 years until the diagnosis (range, 3-33). 
Unfortunately, for the majority of patients (n=28, 80%) there was no information on 
alcohol consumption. None of our patients had had an earlier malignant tumor nor 
had they received earlier radiotherapy in the head and neck area. Five (14%) patients 
had a family history of a malignant tumor, and one of these was in the head and neck 
area (no further details were available). Psychiatric conditions were reported in three 
(9%) patients, other medical conditions (such as high blood pressure) were expressed 
in single patients.  
In 31 (89%) patients the tumor was histologically classified as squamous cell 
carcinoma and four (11%) had a variant of squamous cell carcinoma (e.g. fusocellular 
carcinoma and papillomatous carcinoma). The mean follow-up time until death or the 
last follow-up visit was 18 years (median 15 years; range, 8 months – 46 years). Ten 
(28%) patients experienced LSCC recurrence during follow-up. The median time to 
recurrence was 13 months (mean 25; range, 4-69 months), with the majority of 
recurrences occurring within two years of treatment.  
 
  
  
Discussion 
Studies on young patients with LSCC are scarce as the condition is rare. In studies 
assessing young patients with LSCC, the age limit has commonly been set to 40 years 
or younger (2, 6, 7, 9, 13) and the number of patients in the individual series typically 
tends to be limited, ranging from 20 to 99 (6, 7, 10).This study presents general 
factors of all patients diagnosed with LSCC at the age of 40 years or under in Finland 
over a sixty-year period. Tumor stage and subsite distribution did not differ 
significantly from those previously reported for the general LSCC population in 
Finland (1).  
 
The survival figures of the young patients with LSCC did not differ from the general 
LSCC population in Finland, as is a similar finding in some other studies comparing 
the young and general cohorts (6, 9), although others report a favorable survival in 
younger patients (7, 8) . The 5-year DSS was 88% in the current study and 80% in the 
data recently published for Finnish LSCC patients in general(1).  In a study by 
Nachalon et al., the reported 5-year survival rate was 69%, significantly lower than 
that observed in the control group of older patients (80%) (9). However, Stage III-IV 
disease was predominant in their young patient group (62%), which is in contrast to 
our 151 FCR patients having predominantly Stage 0-II disease (66%). When 
stratifying their survival outcomes according to stage, they observed no differences in 
survival between the young and older patients.  
 
The reported rate of disease persistence or recurrence in LSCC is up to 30% (11, 12). 
This corresponds well with the recurrence rate (28%) in the current material of young 
patients treated at the HUH. Furthermore, the majority of recurrences in patients with 
  
LSCC tend to occur during the first two years (12, 18). In this material, all loco-
regional recurrences occurred during the first six years.  
 
Patients with LSCC have been reported to be at an increased risk for SPCs, the risk 
varying from 1.68 to 1.92-fold reported on population level (3, 19). Our analysis of 
the SPCs with a mean follow-up of 21 years indicates that the majority of SPCs in this 
population occur relatively late, i.e. several decades after the primary LSCC 
diagnosis. This differs from the occurrence of SPCs in the general population of 
LSCC patients, in whom they start occurring already during the first decade after 
LSCC diagnosis. Milano et al. reported the incidence of second primary lung cancer 
after LSCC to be 6%, 11%, and 16% at 5, 10, and 15 years, respectively (20). The 
study of Albright et al., with a follow-up time limited to 15 years, reported LSCC 
patients under the age of 40 to have a lower risk for SPCs compared to older patients 
(8% vs 21%) (2). We, too, noted an almost complete absence of SPCs during these 
first 15 years of follow-up. However, with an extended follow-up up to 59 years with 
a median of 21 years, SPCs occurred in 26% of patients, an occurrence rate 
comparable to the LSCC population in general (11). Young LSCC patients seem to 
develop SPCs at a similar age to the general LSCC population, which is only 
recognized with extended follow-up. Similar to Morris et al., the most common sites 
for SPCs were lung or trachea, comprising 36% of all (19). The majority of the SPCs 
in our cohort patients presented in the lungs concurrent with other published series (3, 
19). Although it is not possible to assess the effect of life-style factors based on our 
data, the presentation age and location of the SPCs in our cohort of young LSCC 
patients may indicate the presence of a cumulative effect of carcinogenic agents. 
 
  
Risk factor assessment in our data was only possible for patients in the institutional 
series. Smoking was common among our patients (83% of the patients with 
information), but our data lacked adequate information on alcohol consumption. 
Nachalon et al.  reported a somewhat lower percentage of smokers (38%) in their 
series of 13 young LSCC patients (9). The comorbidities of our young patients were 
sparse and insignificant: none of our patients had a history of congenital or acquired 
immune deficiency, and neither a history of Helicobacter pylori infection or nor 
papillomatosis which are possible etiological risk factors discussed by other authors in 
the literature (10, 15, 17). HPV status had not been assessed in any of the tumors in 
the current material due to the expected low frequency of HPV positivity in LSCC 
(16). More recent studies show higher rates of HPV in the general LSCC population, 
perhaps reflecting a rise in HPV incidence (16). There have been speculations about 
the genetic vulnerability of young patients with head and neck cancer for malignant 
disease development (13). None of the 35 patients had family members with LSCC or 
any other cancers, except for one patient who had a parent with an unspecified tumor 
in the head and neck area. Ultimately, based on these limited data, we were not able to 
identify any clear distinction between younger and older patients with LSCC with 
regards to etiological factors. 
 
The main strengths of this study are the comprehensive, large cohort of patients and 
the extended follow-up time provided by the FCR, which enables a more thorough 
analysis of SPCs compared with most published studies. Our study suffers a few 
shortcomings. The retrospective nature of this study is a clear limitation. Although the 
institutional data allowed us to estimate the possible significance of smoking and 
comorbidities in the etiology of LSCC in young patients, the data regarding lifestyle 
  
factors were non-comprehensive and incohesive. This hindered the proper assessment 
of their effect on the development of not only primary LSCC but also SPCs. 
However, due to the rareness of LSCC in the young, prospective studies in this patient 
group aiming to report SPCs are not feasible.  
 
 
Conclusions 
 
Location, treatment and outcome of these tumors among young patients did not differ 
from those presented in the literature for the general LSCC patient population. There 
appears to be no rationale for treating young patients differently. Despite the 
abnormally early onset of their laryngeal cancers, SPCs in young patients occurred 
approximately at the same age as in LSCC patients in general. The interval to SPCs 
was thus considerably longer compared with the LSCC population in general. 
Potential factors underlying this phenomenon could not be elucidated in this 
retrospective study and remain as an interesting research area. 
 
Disclosure statement 
 
The authors report no conflict of interest.  
 
 
 
  
  
References 
1. Haapaniemi A, Koivunen P, Saarilahti K, Kinnunen I, Laranne J, Aaltonen 
LM, et al. Laryngeal cancer in Finland: A 5-year follow-up study of 366 patients. 
Head & neck. 2014. 
2. Albright JT, Karpati R, Topham AK, Spiegel JR, Sataloff RT. Second 
malignant neoplasms in patients under 40 years of age with laryngeal cancer. 
Laryngoscope. 2001;111(4 Pt 1):563-7. 
3. Gao X, Fisher SG, Mohideen N, Emami B. Second primary cancers in 
patients with laryngeal cancer: a population-based study. Int J Radiat Oncol Biol 
Phys. 2003;56(2):427-35. 
4. Bradley PJ. Laryngeal cancer in nondrinker nonsmoker young patients: a 
distinct pathological entity? Curr Opin Otolaryngol Head Neck Surg. 
2016;24(2):140-7. 
5. Talamini R, Bosetti C, La Vecchia C, Dal Maso L, Levi F, Bidoli E, et al. 
Combined effect of tobacco and alcohol on laryngeal cancer risk: a case-control 
study. Cancer causes & control : CCC. 2002;13(10):957-64. 
6. Shvero J, Hadar T, Segal K, Abraham A, Sidi J. Laryngeal carcinoma in 
patients 40 years of age and younger. Cancer. 1987;60(12):3092-5. 
7. Lacy PD, Piccirillo JF, Merritt MG, Zequeira MR. Head and neck squamous 
cell carcinoma: better to be young. Otolaryngol Head Neck Surg. 
2000;122(2):253-8. 
8. Misono S, Marmor S, Yueh B, Virnig BA. Treatment and survival in 10,429 
patients with localized laryngeal cancer: a population-based analysis. Cancer. 
2014;120(12):1810-7. 
9. Nachalon Y, Alkan U, Shvero J, Yaniv D, Shkedy Y, Limon D, et al. 
Assessment of laryngeal cancer in patients younger than 40 years. Laryngoscope. 
2018;128(7):1602-5. 
10. Rutt AL, Hawkshaw MJ, Sataloff RT. Laryngeal cancer in patients younger 
than 30 years: a review of 99 cases. Ear Nose Throat J. 2010;89(4):189-92. 
11. Brandstorp-Boesen J, Sorum Falk R, Folkvard Evensen J, Boysen M, 
Brondbo K. Risk of Recurrence in Laryngeal Cancer. PLoS One. 
2016;11(10):e0164068. 
12. Francis DO, Yueh B, Weymuller EA, Jr., Merati AL. Impact of surveillance 
on survival after laryngeal cancer in the medicare population. The Laryngoscope. 
2009;119(12):2337-44. 
13. Wang J, Zhao X, Pan X, Zhao L, Zhou J, Ji M. The role of primary surgical 
treatment in young patients with squamous cell carcinoma of the larynx: a 20-
year review of 34 cases. World J Surg Oncol. 2015;13:283. 
14. Wang Y, Irish J, MacMillan C, Brown D, Xuan Y, Boyington C, et al. High 
frequency of microsatellite instability in young patients with head-and-neck 
squamous-cell carcinoma: lack of involvement of the mismatch repair genes 
hMLH1 AND hMSH2. Int J Cancer. 2001;93(3):353-60. 
15. Zhou J, Zhang D, Yang Y, Zhou L, Tao L. Association between helicobacter 
pylori infection and carcinoma of the larynx or pharynx. Head Neck. 2016;38 
Suppl 1:E2291-6. 
16. Torrente MC, Rodrigo JP, Haigentz M, Jr., Dikkers FG, Rinaldo A, Takes RP, 
et al. Human papillomavirus infections in laryngeal cancer. Head Neck. 
2011;33(4):581-6. 
  
17. Duray A, Descamps G, Arafa M, Decaestecker C, Remmelink M, Sirtaine N, 
et al. High incidence of high-risk HPV in benign and malignant lesions of the 
larynx. Int J Oncol. 2011;39(1):51-9. 
18. Lyhne NM, Johansen J, Kristensen CA, Andersen E, Primdahl H, Andersen 
LJ, et al. Pattern of failure in 5001 patients treated for glottic squamous cell 
carcinoma with curative intent - A population based study from the DAHANCA 
group. Radiother Oncol. 2016;118(2):257-66. 
19. Morris LG, Sikora AG, Patel SG, Hayes RB, Ganly I. Second primary cancers 
after an index head and neck cancer: subsite-specific trends in the era of human 
papillomavirus-associated oropharyngeal cancer. J Clin Oncol. 2011;29(6):739-
46. 
20. Milano MT, Peterson CR, 3rd, Zhang H, Singh DP, Chen Y. Second primary 
lung cancer after head and neck squamous cell cancer: population-based study of 
risk factors. Head & neck. 2012;34(12):1782-8. 
 
 
 
 
 
 
 
 
 
  
  
Figure legends 
 
 
Figure 1. Selection of study populations: the Finnish Cancer Registry data and 
the Helsinki University Hospital data. 
 
Figure 2. Overall survival after diagnosis in patients 40 years of age or younger 
diagnosed with laryngeal squamous cell carcinoma in Finland during 1953-2012 
(n=151). 
 
Figure 3. Disease-specific survival after diagnosis in patients 40 years of age or 
younger diagnosed with laryngeal squamous cell carcinoma in Finland during 
1953-2012 (n=151).  
 
Figure 4. Cumulative incidence of second primary cancers (n=39) in patients 40 
years of age or younger diagnosed with primary laryngeal squamous cell 
carcinoma (n=151). 
 
